Please login to the form below

Not currently logged in
Email:
Password:

Mereo BioPharma’s Richard Bungay to step down

Will leave CFO and COO roles in April 2017

Mereo BioPharma's Richard Bungay is set to step down from his roles as chief financial officer and chief operating officer in April 2017.

Bungay joined the UK-based clinical stage biopharmaceutical firm in July last year, taking on responsibility for Mereo BioPharma's finances, manufacturing and quality operations.

He has previously held the chief financial title at Glide Pharmaceutical Technologies, Chroma Therapeutics and Verona Pharma, remaining as a non-executive board director at both Glide and Chroma.

Prior to these roles, Bungay worked at Celltech Group as director of corporate communications and planning, and served as finance director for AstraZeneca's respiratory and inflammation therapy area.

Dr Peter Fellner, chairman of Mereo BioPharma, said: “On behalf of the board I would like to thank Richard for his significant contributions to the successful launch of the company and the subsequent introduction of its shares on AIM.

“We wish him every success for the future.”

10th October 2016

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Dovetail

We’re a specialist health consultancy that supports companies, healthcare professionals and patients to work hand in hand with a common...

Latest intelligence

The Patient Will See You Now – The Evolution of the Doctor-Patient Relationship
The doctor-patient relationship is an ever changing one that changes as society changes. Technology then helps to drive this change along with a wide number of other factors....
Mind the Gap – Challenging Immunisation Apathy and Misinformation
world, the biggest challenges remain apathy and misinformation. Since a measles vaccine was introduced in the UK in 1968, Public Health England estimates that 20 million measles cases and 4,500...
Towards Better HCP Engagement – An Email Masterclass
6% of HCPs prefer being contacted by email, compared to 17% who favour the second most popular option: direct interaction with reps....